AMR local indicators - produced by the UKHSA | Fingertips | Department of Health and Social Care

Recent updates

September 2024

Mandatory Surveillance Team Annual Epidemiology Commentary (AEC) MRSA, MSSA and Gram-negative bacteraemia and CDI: annual report - GOV.UK (www.gov.uk)

Updated toolkit launched for World AMR Awareness Week which will take place 18-24 November - World Antimicrobial Resistance Awareness Week (WAAW) and European Antibiotic Awareness Day (EAAD) - GOV.UK (www.gov.uk)

August 2024

This year's World AMR Awareness Week (WAAW) to celebrate 10-years of the Antibiotic Guardian campaign taking place on the 25 September 2024

Online Event: Launch of UK nations WAAW 2024 plans and toolkit(s) and celebration of 10-years of the Antibiotic Guardian campaign – Antibiotic Guardian

July 2024

Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q1 2024

Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q1 2024 - GOV.UK (www.gov.uk)

June 2024

Publication of national criteria for prompt intravenous-to-oral switch (IVOS) of antimicrobials in children and young people, and supporting decision aid

Antimicrobial intravenous-to-oral switch: criteria for prompt switch - GOV.UK (www.gov.uk)

May 2024

Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q4 2023

Carbapenemase-producing Gram-negative organisms in England since October 2020: quarterly update, Q4 2023 - GOV.UK (www.gov.uk)

Februrary 2024

Laboratory surveillance of Enterococcus spp. bacteraemia (England): 2022

Laboratory surveillance of Enterococcus spp. bacteraemia (England): 2022 - GOV.UK (www.gov.uk)

Acquired carbapenemase-producing Gram-negative bacteria in England: October 2020 to September 2023

Acquired carbapenemase-producing Gram-negative bacteria in England: October 2020 to September 2023 - GOV.UK (www.gov.uk)

January 2024

Patients can now get treatment for seven common conditions directly from their local pharmacy, without the need for a GP appointment or prescription. The Pharmacy First scheme was launched by the government and NHS England on 31 January 2024 to give patients quick and accessible care and ease pressure on GP services.

https://healthmedia.blog.gov.uk/2024/02/01/pharmacy-first-what-you-need-to-know/

December 2023

Laboratory surveillance of paediatric bacterial bloodstream infections and antimicrobial resistance in England: 2018 to 2022

Paediatric bloodstream infections (England): 2018 to 2022 (publishing.service.gov.uk)

Surveillance of surgical site infections in NHS Hospitals in England annual report for 2022 to 2023 Surgical Site Infections (SSI): NHS Hospitals in England -

Surgical site infections (SSI) surveillance: NHS hospitals in England - GOV.UK (www.gov.uk)

November 2023

Publication of UKHSA's tenth ESPAUR Report 2022 to 2023 English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report - GOV.UK (www.gov.uk)

September 2023

Surveillance of surgical site infections in NHS Hospitals in England annual report for 2022 to 2023 Surgical Site Infections (SSI): NHS Hospitals in England - The 2023 healthcare-associated infections and antimicrobial use national point prevalence survey is taking place between 18 September 2023 and 27 October 2023 in hospitals across England. All acute hospitals (NHS and independent sector) and NHS community and mental health Trusts have been invited to participate this year.

Please see https://www.gov.uk/guidance/point-prevalence-survey-on-hcai-amu-and-ams-in-england for more information and contact details.

August 2023

The 2023 healthcare-associated infections and antimicrobial use national point prevalence survey will be taking place in September 2023 in hospitals across England. All acute hospitals (NHS and independent sector) and NHS community and mental health Trusts have been invited to participate this year.

Please check with your NHS England or UKHSA regional leads to find out more or contact the HCAI and AMU PPS team at HCAI_PPS@ukhsa.gov.uk.

Updates to two national antimicrobial stewardship (AMS) tool were published on Tuesday 15 August 2023:

Start Smart The Focus AMS Toolkit for Inpatient Care Settings https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus

Antimicrobial Prescribing and Stewardship (APS) Competency Framework https://www.gov.uk/government/publications/antimicrobial-prescribing-and-stewardship-competencies

AMR local indicators - produced by the UKHSA

About the AMR local indicators

Data have been uploaded across six domains: The AMR local indicators are produced by the UKHSA.

Supporting NHS England Initiatives
Antimicrobial Resistance (AMR)
Antibiotic Prescribing
Healthcare-Associated Infections (HCAI)
Infection Prevention and Control (IPC)
Antimicrobial stewardship (AMS)

Antibiotic prescribing and antibiotic resistance are inextricably linked, as overuse and incorrect use of antibiotics are major drivers of resistance. AMR local indicators are publically available data intended to raise awareness of antibiotic prescribing, AMR, HCAI, IPC and AMS; and to facilitate the development of local action plans. The data published in this tool may be used by healthcare staff, commissioners, directors of public health, academics and the public to compare the situation in their local area to the national picture.

For further information about this profile, please click here to download the user guide.

Updated indicators

September 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Antibiotic Prescribing Area: Acute Trusts upto Q2 2024/25 (cy)

Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust

AWaRe and broad-spectrum prescribing

Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust
Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust

"For the indicators in the topics Antibiotic Prescribing and Supporting NHS England Initiatives in the area Acute Trusts (Indicators 93555, 93868, 93824, 93557, 93633, 93632 and 93556) we are aware of data quality concerns with 9 trusts. These will be rectified at the next upload period at the beginning of November 2024."

Supporting IVOS CQUIN

Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust

Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q2 2024/25 (cy)

Total number of prescribed antibiotic items per STAR-PU by quarter
Total number of prescribed antibiotics items per 1000 resident individuals by quarter
Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class

Topic: Antibiotic Prescribing Area: GP up to Q2 2024/25 (cy)

Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
Total number of prescribed antibiotic items per 1000 registered patients by quarter
Total number of prescribed antibiotic items per STAR-PU by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin

“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution. Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”

Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to July 2024

Area – ICB sub-locations

C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

"Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.”

Area – Acute Trusts

C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
C. difficile toxin tests per 1,000 bed-days carried out by reporting acute trust and quarter
Blood culture sets per 1,000 bed-days performed by reporting acute trust and quarter

Topic: Antimicrobial Resistance Area: ICB sub-locations level covering upto Q2 2024 period

1. E. coli, blood, testing, carbapenem, quarterly, percentage

2. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage

3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage

4. E. coli, blood, testing, Gentamicin, quarterly, percentage

5. E. coli, blood, testing, Piperacillin/Tazobactam, quarterly, percentage

6. E. coli, urine, testing, trimethoprim, quarterly, percentage, community

7. E. coli, urine, resistance, trimethoprim, quarterly, percentage, community

8. E. coli, urine, testing, nitrofurantoin, quarterly, percentage, community

9. E. coli, urine, resistance, nitrofurantoin, quarterly, percentage, community

10. E.coli, blood, resistance, 1 Antibiotics, rolling quarterly, percentage

11. E.coli, blood, resistance, 3 or more antibiotics classes, rolling quarterly, percentage

12. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage

13. E.coli, blood, resistance,Ciprofloxacin, rolling quarterly, percentage

14. E.coli, blood, resistance, Gentamicin, rolling quarterly, percentage

15. E.coli, blood, resistance, Piperacillin/Tazobactam, rolling quarterly, percentage

Topic: Antimicrobial Resistance Area: Acute Trusts covering upto Q2 2024 period

1. E. coli, blood, testing, Gentamicin, quarterly, percentage

2. E. coli, blood, testing, carbapenem, quarterly, percentage

3. E. coli, blood, testing, Ciprofloxacin, quarterly, percentage

4. E. coli, blood, testing, piperacillin/tazobactam, quarterly, percentage

5. E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage

6. E.coli, blood, resistance, Ciprofloxacin, rolling quarterly, percentage

7. E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage

8. E.coli, blood, resistance, piperacillin/tazobactam, rolling quarterly, percentage

9. E. coli, blood, resistance, Gentamicin, quarterly, percentage

August 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Infection Prevention and Control Area: Acute Trusts upto 2023 (cy)

Proportion of single rooms available within NHS Acute Trusts by financial year
Proportion of single rooms available with ensuite NHS Acute Trusts by financial year
PLACE Cleanliness Scores, by NHS Acute Trust

Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to June 2024

Area – ICB sub-locations

C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

Area – Acute Trusts

C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month

July 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Antibiotic Prescribing Area: Acute Trusts upto Q1 2024/25 (cy)

Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust

AWaRe and broad-spectrum prescribing

Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust

Supporting IVOS CQUIN

Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust

Topic: Antimicrobial Stewardship and Supporting NHS England Initiatives Area: ICB sub-locations Q4 2023

Antibiotic Guardians per 100,000 population per quarter by ICB
Antibiotic Guardians per 100,000 population per calendar year by ICB

Topic: Antimicrobial Stewardship and Supporting NHS England Initiatives Area: Acute Trusts Q4 2023/24

CQUIN 2023/24 03: Percentage of patients still receiving intravenous (IV) antibiotics past the point at which they meet IV-oral switch criteria

Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q1 2024/25 (cy)

Total number of prescribed antibiotic items per STAR-PU by quarter
Total number of prescribed antibiotics items per 1000 resident individuals by quarter
Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class

Topic: Antibiotic Prescribing Area: GP up to Q1 2024/25 (cy)

Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
Total number of prescribed antibiotic items per 1000 registered patients by quarter
Total number of prescribed antibiotic items per STAR-PU by quarter
Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin

Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to May 2024

Area – ICB sub-locations

C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

Area – Acute Trusts

C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month

June 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Healthcare Associated Infections Area: Acute Trusts, ICB sub-locations up to April 2024

Area – ICB sub-locations

C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

Area – Acute Trusts

C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
C. difficile toxin tests per 1,000 bed-days carried out by reporting acute trust and quarter
Blood culture sets per 1,000 bed-days performed by reporting acute trust and quarter

Topic: Antimicrobial Resistance Area: ICB sub-locations level covering upto Q1 2024 period